p53 Review Article

You have free access to this content

TP53 mutations in familial breast cancer: Functional aspects†

  1. Milena Gasco1,
  2. Isik G Yulug2,
  3. Tim Crook3,*

Article first published online: 24 FEB 2003

DOI: 10.1002/humu.10173

Issue

Human Mutation

Human Mutation

Special Issue: Focus on p53 and Cancer

Volume 21, Issue 3, pages 301–306, March 2003

Additional Information

How to Cite

Gasco, M., Yulug, I. G. and Crook, T. (2003), TP53 mutations in familial breast cancer: Functional aspects. Hum. Mutat., 21: 301–306. doi: 10.1002/humu.10173

Author Information

  1. 1

    Department of Medical Oncology, Azienda Ospedaliera San Croce e Carle, Cuneo, Italy

  2. 2

    Department of Molecular Biology and Genetics, Bilkent University, Ankara, Turkey

  3. 3

    Ludwig Institute for Cancer Research, Imperial College Faculty of Medicine, Norfolk Place, London, UK

*Ludwig Institute for Cancer Research, Imperial College Faculty of Medicine, Norfolk Place, London, W21PG, UK

  1. †

    For the p53 Special Issue

Publication History

  1. Issue published online: 24 FEB 2003
  2. Article first published online: 24 FEB 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (112K)

REFERENCES

  • Aurelio ON, Kong XT, Gupta S, Stanbridge EJ. 2000. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol Cell Biol 20:770–778.
  • Borresen-Dale AL. 2003. TP53 and breast cancer. Hum Mutat 21:292–300.
    Direct Link:
  • Campomenosi P, Monti P, Aprile A, Abbondandolo A, Frebourg T, Gold B, Crook T, Inga A, Resnick MA. 2001. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 20:3573–3579.
  • Crook T, Marston NJ, Sara EA, Vousden KH. 1994. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79:817–827.
  • Crook T, Brooks LA, Crossland S, Osin P, Barker KT, Waller J, Philp E, Smith PD, Yulug I, Peto J, Parker G, Allday MJ, Crompton MR, Gusterson BA. 1998. p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumors. Oncogene 17:1681–1689.
  • de Cremoux P, Salomon AV, Liva S, Dendale R, Bouchind'homme B, Martin E, Sastre-Garau X, Magdelenat H, Fourquet A, Soussi T. 1999. p53 mutation as a genetic trait of typical medullary breast carcinoma. J. Natl. Cancer Inst 91:641–643.
  • Finlay CA, Hinds PW, Levine AJ. 1989. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083–1093.
  • Gasco M, Shami S, Crook T. 2002. The p53 pathway in breast cancer. Breast Cancer Res 4:70–76.
  • Glebov OK, McKenzie KE, White CA, Sukumar S. 1994. Frequent p53 gene mutations and novel alleles in familial breast cancer. Cancer Res 54:3703–3709.
  • Greenblatt MS, Chappuis PO, Bond JP, Hamel N, Foulkes WD. 2001. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res 61:4092–4097.
  • Gretarsdottir S, Thorlacius S, Valgardsdottir R, Gudlaugsdottir S, Sigurdsson S, Steinarsdottir M, Jonasson JG, Anamthawat-Jonsson K, Eyfjord JE. 1998. BRCA2 and p53 mutations in primary breast cancer in relation to genetic instability. Cancer Res 58:859–862.
  • Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Waakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rosant J, Mak TW. 1996. The tumor suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse. Cell 85:1009–1023.
  • Hakem R, de la Pompa JL, Eliaa A, Potter J, Mak TW. 1997. Partial rescue of BRCA1 (5–6) early embryonic lethality by 53 or p221 null mutation. Nat Genet 16:298–302.
  • Inga A, Storici F, Bourna B, Darden T, Resnick MA. 2002. A sensitive in vivo system determines the transactivation specificity and selectivity of human p53 alleles at many promoter elements. Proc Am Assoc Cancer Res 43:1140–1141.
  • Ko LJ, Prives C. 1996. p53: puzzle and paradigm. Genes Dev 10:1054–1072.
  • Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayanath P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MK. 1994. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71.
  • Monti P, Campomenosi P, Ciribilli Y, Iannone R, Inga A, Abbondandolo A, Resnick MA, Fronza G. 2002. Tumour p53 mutations exhibit promoter selective dominance over wild type p53. Oncogene 21:1641–1648.
  • Pharoah PD, Day NE, Caldas C. 1999. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 80:1968–1973.
  • Phillips KA, Nichol K, Ozcelik H, Knight J, Done SJ, Goodwin PJ, Andrulis IL. 1999. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J Natl Cancer Inst (Bethesda) 91:469–473.
  • Ramus SJ, Bobrow LG, Pharoah PD, Finnigan DS, Fishman A, Altaras M, Harrington PA, Gayther SA, Ponder BA, Friedman LS. 1999. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumors. Genes Chromosomes Cancer 25:91–96.
    Direct Link:
  • Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, Vousden KH. 1996. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 15:827–838.
  • Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh J-K, Zhong S, Campargue I, Naumovski L, Crook T, Lu X. 2001. ASPP proteins specifically stimulate the apoptotic function of p53. Mol Cell 8:781–794.
  • Schlichtholz B, Bouchind'homme B, Pages S, Martin E, Liva S, Magdelenat H, Sastre-Garau X, Stoppa-Lyonnet D, Soussi T. 1998. p53 mutations in BRCA1-associated familial breast cancer. Lancet 352:622.
  • Sigal A, Rotter V. 2000. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60:6788–6793.
  • Smith PD, Crossland S, Parker G, Osin P, Brooks L, Waller J, Philp E, Crompton MR, Allday MJ, Crook T. 1999. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene 18:2451–2459.
  • Suzuki A, de la Pompa JL, Hakem R, Elia A, Yoshida R, Mo R, Nishina H, Chuang T, Wakeham A, Itie A, Koo W, Billia P, Ho A, Fukumoto M, Hui CC, Mak TW. 1997. BRCA2 is required for embryonic cellular proliferation in the mouse. Genes Dev 11:1242–1252.
  • Szak ST, Mays D, Pietenpol JA. 2001. Kinetics of p53 binding to promoter sites in vivo. Mol Cell Biol 21:3375–3386.
  • Vogelstein B, Lane D, Levine AJ. 2001. Surfing the p53 network. Nature 408:307–310.
  • Vousden KH, Lu X. 2002. Live or let die: the cell's response to p53. Nat Rev Cancer 2:594–604.
  • Walker DR, Bond JP, Tarone RE, Harris CC, Makalowski W, Boguski MS, Greenblatt MS. 1999. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 structural and functional features. Oncogene 18:211–218.
  • Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G, Barfoot R, Hamoudi R, Patel S, Rice C, Biggs P, Hashim Y, Smith A, Connor F, Arason A, Gudmundsson J, Ficenec D, Kelsell D, Ford D, Tonin P, Bishop DT, Spurr NK, Ponder BAJ, Eeles R, Peto J, Devilee P, Cornelisse C, Lynch H, Narod S, Lenoir G, Egilsson V, Barkadottir DR, Futreal PA, Ashworth A, Stratton MR. 1995. Identification of the breast cancer susceptibility gene BRCA2. Nature 378:21–28.
  • Xu X, Wagner KU, Larson D, Weaver Z, Li C, Reid T, Henighausen L, Wynshaw-Boris A, Deng CX. 1999. Conditional mutation in Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumor formation. Nat Genet 22:37–43.
  • Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi D, Weber BL, El-Deiry WS. 1998. BRCA1 physically associates with p53 and stimulates its transcriptional activity. Oncogene 16:1713–1721.
  • Zweemer RP, Shaw PA, Verheijen RM, Ryan A, Berchuk A, Ponder BA, Risch H, McLaughlin JR, Narod SA, Menko FH, Kenemans P, Jacobs IJ. 1999. J Clin Pathol (London) 52:372–375.
Get PDF (112K)